mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies
The Lancet Microbe · 2026-07 · 101467
DOI: 10.1016/j.lanmic.2026.101467 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026-07. Verfasst von Benjamin Davido und 6 weiteren Autor:innen. Beteiligte Einrichtung: Maladies Infectieuses, Hôpital Raymond-Poincaré, Université Paris Saclay, AP-HP, Garches, France; UMR1173, Université Versailles Saint-Quentin, Monti…. Hauptthemen laut MEDLINE: Drug Resistance, Multiple, Bacterial, Bacterial Vaccines, Microbiota, Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance (AMR) has made multidrug-resistant organisms (MDROs), particularly ESKAPE-E pathogens (including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp, and Escherichia coli), a major threat to modern medicine. Although novel antibiotics, antimicrobial stewardship, and infection prevention remain essential, such interventions are unlikely to offset projected AMR trends on their own. Vaccines can help to mitigate AMR by preventing infections and reducing antibiotic exposure. WHO estimates that vaccines targeting 23 pathogens (excluding Neisseria gonorrhoea) could reduce global antibiotic need by 22%, equivalent to 2·5 billion defined daily doses annually. In the mRNA era, modular vaccine platforms enable rapid design of protein antigens and multivalent constructs, with emerging preclinical proof of concept against selected bacterial pathogens. In this Personal View, we argue that mRNA vaccines should be considered enabling platforms for selected protein-based MDRO targets rather than universal solutions for antibacterial vaccine development. We propose a microbiome-informed framework that distinguishes systemic protection from mucosal decolonisation and aligns antigen selection, delivery route, and trial endpoints with colonisation dynamics, microbiome resilience, and AMR reduction goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Maladies Infectieuses, Hôpital Raymond-Poincaré, Université Paris Saclay, AP-HP, Garches, France; UMR1173, Université Versailles Saint-Quentin, Montigny-Le-Bretonneux, France; Mission Ministérielle de la Prévention des…
- Virulence Bactérienne et Infections Chroniques, INSERM0, Univ Montpellier, Service des Maladies Infectieuses et Tropicales, CHU Nîmes, Nîmes, France.
- UMR1173, Université Versailles Saint-Quentin, Montigny-Le-Bretonneux, France.
- Mission Ministérielle de la Prévention des infections et de l'antibiorésistance, Direction Générale de la Santé, Paris, France; Aix Marseille Université, INSERM, SSA, MCT, Marseille, France.
- UMR1173, Université Versailles Saint-Quentin, Montigny-Le-Bretonneux, France; SEPSIS Comprehensive Center - IHU SEPSIS, Garches, France; Service de Microbiologie, Hôpital Raymond-Poincaré, Université Paris Saclay, AP-HP…
- Department of Medical Sciences, University of Turin, Italy; Tufts University School of Medicine, Boston, MA, USA.
Zitieren
APA
Davido, B., Loubet, P., Saleh-Mghir, A., Leroux, P., Rottman, M., Corcione, S., & European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interactions (ESGHAMI) (2026). mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies. The Lancet Microbe, 101467. https://doi.org/10.1016/j.lanmic.2026.101467
Vancouver
Davido B, Loubet P, Saleh-Mghir A, Leroux P, Rottman M, Corcione S, et al. mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies. The Lancet Microbe. 2026:101467. doi:10.1016/j.lanmic.2026.101467
BibTeX
@article{Davido2026,
author = {Davido, Benjamin and Loubet, Paul and Saleh-Mghir, Azzam and Leroux, Pierre and Rottman, Martin and Corcione, Silvia and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interactions (ESGHAMI), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interactions (ESGHAMI)},
title = {mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies},
journal = {The Lancet Microbe},
year = {2026},
pages = {101467},
doi = {10.1016/j.lanmic.2026.101467}
}
EUVIMED